Stemline Therapeutics

Stemline Therapeutics, Inc. is a clinical biopharmaceutical company and a leading developer of novel oncology compounds targeting cancer stem cell targets. Stemline's lead compound, SL-401, targets the interleukin-3 receptor present in various hematologic cancers (including leukemic blasts and leukemic stem cells). SL-401 has demonstrated single-agent anti-tumor activity at tolerable doses in a multicenter Phase I human trial.Behind its leadership position, Stemline is developing a broad portfolio of compounds targeting high-value cancer stem cell targets across this blood-related and various other hematologic and solid tumor cancers. Additionally, Stemline has established a robust discovery platform called "StemScreen®," which the company has utilized to identify multiple compounds that target and impair cancer stem cells.Stemline also holds a comprehensive intellectual property portfolio, including some of the earliest filings in the cancer stem cell field, covering cancer stem cell-directed therapies, diagnostics, and drug screening. Stemline’s key drug, Elzonris, is used to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive bone marrow and blood disease, in adults and children aged 2 years and older.Elzonris is currently the first approved treatment for BPDCN. It is designated as an orphan drug in both the United States and Europe. In August 2016, the drug was granted Breakthrough Therapy Designation by the FDA, and in August 2018, it received Priority Review.In December 2018, Elzonris received FDA approval. In January 2019, Elzonris launched in the U.S., generating $11.8 million in net revenue for Stemline in the fourth quarter of 2019.